国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (8): 649-652.

• 综述 • 上一篇    下一篇

趋化因子CXCL12与肿瘤

赵泰成, 白鹰   

  1. 116021大连大学附属新华医院神经内三科
  • 出版日期:2013-09-08 发布日期:2013-09-16
  • 通讯作者: 白鹰,E-mail: yingbai99@yahoo.com E-mail:yingbai99@yahoo.com

Chemokine CXCL12 in cancer

ZHAO  Tai-Cheng, BAI  Ying   

  1. Department of Neurology, Xinhua Hospital, Dalian University, Dalian 116021, China

  • Online:2013-09-08 Published:2013-09-16
  • Contact: Corresponding author: BAI Ying, E-mail: yingbai99@yahoo.com E-mail:yingbai99@yahoo.com

摘要: 趋化因子CXCL12又称基质细胞衍生因子-1,是一个定位于10号染色体由基质细胞产生的CXC类趋化因子。目前认为CXCR4和CXCR7是CXCL12的两个受体。多项研究发现CXCL12在肿瘤细胞增殖、转移及血管生成过程中发挥重要作用。因此,CXCL12有望成为肿瘤基因治疗的新靶点。

关键词: 肿瘤, 细胞增殖, 肿瘤转移, 新生血管化, 病理性

Abstract: CXCL12, also known as stromal cell-derived factor 1, is a member of the CXC family, which locates on the 10th chromosome and produces by the stromal cells. It is known that CXCR4 and CXCR7 are the two receptors of chemokine CXCL12. Many studies show that the chemokine CXCL12 plays an important role in cancer progression, including proliferation, metastasis and angiogenesis. Therefore, the chemokine CXCL12 is expected to become a novel target for the gene therapy of cancer.

Key words: Neoplasms, Cell proliferation, Neoplasm metastasis, Neovascularization, pathologic